Dow Dull Except for...
Health Care: Drugs
Celgene Corporation (CELG: NASDAQ)
$123.12 -1.79 | -1.43%
05/20/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 124.91 |
| 52 Week High | 131.82 |
| 52 Week Low | 58.53 |
| Avg. Daily Vol. (Mil) | 3.28 |
| Beta (3 year) | 0.92 |
| Share Related Items | |
| Mkt Cap (Mil) | 52,102.77 |
| Shares Out (Mil) | 417.12 |
| Float (Mil) | 416.68 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.90 |
| Current Ratio | 3.40 |
| LT Debt/ Equity | 0.50 |
| Total Debt / Equity | 0.56 |
| Valuation Ratios | |
| Price Earnings | 38.00 |
| Price/Sales | 9.14 |
| Price/Book | 9.38 |
| Price/Cash Flow | 29.70 |
| Per Share Data | |
| Earnings | 3.29 |
| Sales | 13.66 |
| Book Value | 13.32 |
| Cash Flow | 4.20 |
| Business Summary | |
|---|---|
| Celgene Corporation is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. | |
| General Information | |
| 86 Morris Avenue
Summit, NJ 07901 |
|
| www.celgene.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 4700 | |
| CEO: Robert J. Hugin | |
| Short Interest | |
| Current Month (Mil) | 4.32 |
| Previous Month (Mil) | 5.80 |
| Short Interest Ratio (Days) | 1.30 |
| Management Effectiveness | |
| Return on Equity | 25.90 |
| Return on Assets | 12.60 |
| Return on Investments | 17.30 |
| Profitability | |
| Gross Margin | 96.30 |
| EBIT Margin | 30.30 |
| Profit Margin | 25.30 |
Portfolios with CELG
- Portfolio NameUser Type
- Userdennis all star
- Userportfolio 1.1
- UserCraigMcIlquham
- User4 Overvalued Biotechs
- ProRay Dalio - Bridgewater Ass...
- ProBill Miller - Legg Mason Ca...
- ContributorStocks Rising On Unusual Vo...
- UserTest Portfolio
- UserMike Fatah's Mega Stock Por...
- User2012 Allocation
Latest CELG Headlines from TheStreet
- Celgene Corporation (CELG): Today's Featured Health Care Laggard 04.18.13 | 05:04 pm
- The Next Big Thing In Biotech: Large-Cap Earnings
04.18.13 | 09:04 am - 5 Stocks Pushing The Drugs Industry Downward 04.15.13 | 01:04 pm
- Cramer's 6 Stocks in 60 Seconds: UA ADBE FTNT ACAD CELG RLGY (Update 1) 04.11.13 | 05:04 pm
- Health Care Standout Celgene Corporation (CELG) Making Gains Today 04.11.13 | 05:04 pm
- Celgene Corporation Stock Buy Recommendation Reiterated (CELG) 04.11.13 | 10:04 am
- Celgene Reaches New 52-Week High (CELG) 04.10.13 | 11:04 am
- Market Takes Aim at Historic Highs Once Again 04.10.13 | 09:04 am
- Risk Of A Major Stock Correction Is Growing 04.09.13 | 01:04 pm
- Biotech Multiples Are Soaring But M&A Is Dead 04.08.13 | 12:04 pm
Press Releases for CELG
- Celgene Corporation To Webcast At Two Upcoming Investor Conferences And The American Academy Of Dermatology Annual Meeting - Business Wire 02.28.13 | 08:02 am
- Celgene Announces $600 Million Accelerated Share Repurchase Program - Business Wire 02.20.13 | 08:02 am
- Celgene Provides REVLIMID® Regulatory Update - Business Wire 02.11.13 | 07:02 am
- POMALYST(R) Brand Therapy (Photo: Business Wire) - Business Wire 02.08.13 | 03:02 pm
- Celgene Corporation To Webcast At Upcoming Investor Conferences - Business Wire 02.04.13 | 08:02 am
- Celgene Reports Strong Fourth Quarter And Full Year 2012 Operating And Financial Results - Business Wire 01.24.13 | 07:01 am
- The True Effect: Positive Findings - Research Report On Celgene Corporation And Gilead Sciences, Inc. - PR Newswire 01.23.13 | 08:01 am
- ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage In Phase III Study Of Patients With Advanced Pancreatic Cancer - Business Wire 01.22.13 | 06:01 pm
- Celgene Corporation Announces Financial Outlook And Preliminary 2012 Results - Business Wire 01.07.13 | 11:01 am
- Celgene Corporation To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.21.12 | 08:12 am
Partner Headlines for CELG
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Stocks On The Move Table Identifies Emerging Leaders - Investor's Business Daily 04.10.13 | 05:04 pm
- How The IBD 50 Can Help Investors Find Winning Stocks - Investor's Business Daily 04.05.13 | 04:04 pm
- Stocks Open Sharply Lower After Employment Report - Investor's Business Daily 04.05.13 | 10:04 am
- Benzinga's Top Upgrades - Benzinga 04.05.13 | 08:04 am
- Can New Psoriasis Drugs Scratch Investors' Itch? - Investor's Business Daily 04.04.13 | 01:04 pm
- Top Funds' New Buys: Lumber Liquidators, Celgene - Investor's Business Daily 04.02.13 | 06:04 pm
- U.S. Mutual Funds Up 10% In Q1; Managers' Top Buys - Investor's Business Daily 04.02.13 | 06:04 pm
